Socioeconomic, clinical, and parental mental health factors affect neurodevelopmental and mental health outcomes among children with CHD.

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.